Anteris Technologies Looks Bullish If DurAVR's PARADIGM Delivers

Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in ...
Clinical Trials Arena on MSN

Paradigm Health debuts post-marketing study tool for routine care integration

SPIRE is designed to allow more routine care providers in community and rural settings to participate in post-marketing ...

Paradigm Health Launches SPIRE to Accelerate Late-Phase Clinical Evidence Generation

Paradigm Health today announced SPIRE -- Scalable Platform for Integrated Research & Evidence -- a new model for post-approval and late-stage clinical studies designed to help sponsors generate ...
Seeking Alpha

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), ...
Morningstar

New Peer-Reviewed Research Demonstrates Effectiveness of Paradigm Health Study Conduct Products

COLUMBUS, Ohio and NEW YORK, April 8, 2026 /PRNewswire/ -- New peer-reviewed research demonstrates the feasibility and effectiveness of Paradigm Health's EHR-integrated eSource platform to support ...
Morningstar

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower ...
Nasdaq

AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive ...